This report presents an overview of the market environment for vaccine makers in China. It discusses vaccine recommendations and coverage, the regulatory situation, pricing an reimbursement and vaccine distribution in China. It analyzes portfolios, pipelines, strategies and local deals of both domestic and multinational vaccine companies and suggests strategies for optimal market penetration.
Features and benefits
- Review the current regulatory process, pricing, vaccination recommendations and coverage in China.
- Examine the major drivers and resistors of the current Chinese vaccine market. Understand the key opportunities and threats facing developers.
- Develop commercial strategies for operating in the Chinese vaccines market.
Highlights
- China is the largest vaccine consumer in the world. It is a closed market with a strong local vaccine industry, access to which is challenging for Western players. While state-owned companies dominate the category 1 vaccine market, privately owned and foreign vaccine manufacturers play a significant role in the category 2 vaccine market.
- GlaxoSmithKline is the biggest multinational vaccine player in China, with 23 million doses of vaccine approved in 2010. The company’s most successful vaccines in China are its MMR, hepatitis B and A vaccines. Among domestic vaccine players, CNBG and Sinovac excel in terms of category 1 vaccine supply and strong R&D capacities.
- In order to penetrate the Chinese market, partnerships with local vaccine companies are crucial for Western vaccine manufacturers. Datamonitor believes that hospitals in second- and third-tier cities will be the next target for multinational companies. New GMP guidelines will further increase M&A opportunities for multinationals.
Your key questions answered
- What are the key domestic and multinational companies active in the vaccine development?
- What are the resistors and drivers of the Chinese human vaccine market?
- How are vaccines categorized in China? What is the regulatory process of vaccine development?
Read Comprehensive Table of Contents, Request a Sample or Inquire before buying the report 'Vaccine Market Access in China – M&A paves the way for foreign companies' @ http://www.reportsnreports.com/reports/139177-vaccine-market-access-in-china-ma-paves-the-way-for-foreign-companies.html
